CD274 and renal carcinoma: At present, immune checkpoint blockade therapy (PD-1, PD-L1, and CTLA4) has been successfully applied to renal cancer patients with certain results (Kammerer-Jacquet et al., 2019; Tucker and Rini, 2020).